Skip to main content
OpenTrials
Completed

NCT Number: NCT01602159

Revascularization With Open Bypass Versus Angioplasty and STenting of the Lower Extremity Trial (ROBUST)

This is a prospective randomized controlled trial to compare clinical improvement, cost effectiveness and patency rates between new and improved Nitinol stents and open bypass surgery in the superficial femoral artery disease.

Secondary outcomes also include comparing quality of life, re-intervention rate, mortality, morbidity and time to return to work or regular activities.

Patients with superficial femoral artery lesions will be considered. Patients with TASC II A lesions will not be randomized but treated with PTA/stenting as standard of care. Patients with TASC II B and C lesions will be prospectively randomized into either receiving open bypass or stenting.

Patients with TASC D lesions will be treated with open bypass surgery after angiography.

The investigators will collect pre-procedure, peri-procedural and clinical follow-up data on all enrolled the patients.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical Inclusion:

  • Must be at least 18 years of age.
  • Patient has been informed of the nature of the study, and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB)/Medical Ethics Committee (MEC) of the respective clinical site.
  • Symptomatic patient as evidence by IC or CLI.
  • Patient has failed maximized medical treatment and exercise program.
  • Patient has a resting ABI < 0.9 or an abnormal exercise ABI if resting ABI is normal.Patient with non-compressible arteries (ABI > 1.2) must have a TBI < 0.8.
  • Patient has a de novo or restenotic lesion(s) with > 50% stenosis documented angiographically.
  • Patient agrees to return for all required clinical contacts following study enrollment.
  • Patient has no childbearing potential or has a negative pregnancy test within one week prior to the study procedure.

Anatomical Inclusion:

  • Patient with any SFA lesion
  • At least one tibial vessel runoff with < 50% stenosis
  • Lesion starts start at least 1 cm distal to the deep femoral artery
  • Lesion end at least 3 cm above the knee joint
  • Target vessel reference diameter is > 3 mm & < 6.5 mm

Exclusion criteria

Clinical exclusion:

  • Known allergic reaction to anesthesia not able to overcome by medication.
  • Known allergic reaction to contrast not able to overcome by medication.
  • Known history of intolerance to study medicating including ASA, clopidogrel, or ticlopidine.
  • Bleeding disorder or refuses blood transfusion.
  • Prior stenting or bypass of SFA (prior PTA is not an exclusion criteria)
  • Unstable angina, recent MI within a month
  • Malignancy or other condition limiting life expectancy to < 5 years.
  • Renal insufficiency (serum Cr > 2.0)
  • Patient has any condition that precludes proper angiographic assessment or makes percutaneous arterial access unsafe (e.g., morbid obesity).

Anatomic Exclusion:

  • Lesion < 1 cm from origin of DFA
  • Lesion < 3 cm from the knee joint
  • Chronic total occlusion of SFA > 20cm.
  • Chronic total occlusion of CFA.
  • Proximal trifurcation occlusions.

Treatment and study plan

Open Bypass Surgery

Procedure

Open Bypass Surgery with Autogenous vein or PTFE Graft

Angioplasty and Stenting

Procedure

Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).

Other names: Life Stent flexStar Stent System by Bard Inc. Tempe AZ

Primary outcomes

  1. Clinical improvement

    Time frame: 12 Month Post Operatively

    Clinical Improvement is measured as at least 1 Rutherford category

  2. Patency rate

    Time frame: 12 Month Post Operatively

    Primary, primary assisted and secondary at 6, 12 month

  3. Cost effectiveness

    Time frame: 12 Month Post Operatively

    Cost Effectiveness factoring procedure and hospital admission costs

Secondary outcomes

  1. Quality of Life improvement

    Time frame: 12 Month Post Operatively

    Improvement of quality of life measured using VQL

  2. Re-intervention rate

    Time frame: 12 Month Post Operatively

  3. Technical success of both treatment modalities

    Time frame: 12 Month Post Operatively

  4. 30-day operative mortality

    Time frame: 12 Month Post Operatively

  5. Time to return to work and regular activities

    Time frame: 12 Month Post Operatively

  6. Morbidity associated with both treatment modalities

    Time frame: 12 Month Post Operatively

Sponsors and collaborators

Lead sponsor

Johns Hopkins University

Other

Registry information

Acronym: ROBUST

Important dates

Study start
2009
Primary completion
2014
Study completion
2014
First posted
May 18, 2012
Registry last updated
Sep 28, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.